Novartis' Kisqali Scores Big Win In Competitive CDK4/6 Space
Data at ASCO showed a statistically significant overall survival advantage in pre- and perimenopausal women with advanced HR+, HER2- breast cancer, a first for the CDK4/6 class.
You may also be interested in...
Novartis’ Kisqali Could Challenge Pfizer’s Ibrance After Phase II First-Line Aggressive Breast Cancer Success
The Swiss major’s CDK4/6 inhibitor has met the primary endpoint in a Phase II trial in first-line aggressive advanced breast cancer, supporting off-label use as the firm goes head to head with Pfizer’s rival drug Ibrance.
Novartis All Smiles After Kisqali OS Success In MONALEESA-2
After the presentation of stellar long-term survival data at ESMO for Kisqali in women with HR+/HER2- advanced breast cancer, Novartis is planning to knock Pfizer's Ibrance off its CDK4/6 inhibitor perch with the help of a head-to-head trial.
Survival Data Boost Lilly & Novartis’s CDK4/6 Assault On Pfizer’s Ibrance In Metastatic Breast Cancer
Pfizer’s dominance of the CDK4/6 inhibitor market will come under renewed pressure as the MONALEESA-3 and MONARCH-2 studies for Novartis’s Kisqali and Lilly’s Verzenio presented at ESMO confirmed their survival benefits in advanced hormone-receptor-positive, HER2-negative breast cancer. The data firmly push the drug class into front-line advanced setting in these patients.